[속보] WHO Advisory Committee “AZ Vaccine Has Great Potential to Reduce Death

Following the European Medicines Agency (EMA), vaccine experts from the World Health Organization (WHO) also commented on the novel coronavirus infection (Corona 19) vaccine developed by AstraZeneca on the 19th (local time), “Globally prevents infection and dies. It has tremendous potential to reduce the amount of money,” he said positively.

In a statement that day, the Corona 19 subcommittee of the WHO Vaccine Safety Advisory Committee (GACVS) explained in a statement that “AstraZeneca vaccine continues to receive positive reviews in the benefit-risk profile.”

“The available data do not suggest an overall increase in thrombotic diseases such as deep venous thrombosis or pulmonary embolism after COVID-19 vaccine administration.”

The subcommittee also explained that the incidence of thromboembolic events reported after vaccination with COVID-19 is close to the expected number of diagnoses for these diseases.

He also stressed that “a very rare and specific thromboembolic disease, combined with thrombocytopenia, such as cerebral venous sinus thrombosis, has been reported in Europe after AstraZeneca’s COVID-19 vaccination, but it is not clear whether it is due to vaccination.” .

Still, the subcommittee urged countries to continue to monitor the safety of all COVID-19 vaccines and report any suspected abnormalities. “We agree with EMA’s plans to further investigate and monitor these phenomena.”

Reporter Han Young-hye [email protected]